±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 457  |  »Ø¸´: 2
¡¾½±Àø¡¿ ±¾Ìû±»ÆÀ¼Û2´Î£¬×÷ÕßuouononoÔö¼Ó½ð±Ò 1.6 ¸ö

uouonono

ľ³æ (ÖøÃûдÊÖ)


[×ÊÔ´] EBR - April 2019

The European Biopharmaceutical Review (EBR), is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the pan European biopharmaceutical market across Europe, North America & the rest of the developed world. The editorial covers in-depth articles, case studies, meeting and report reviews written by specialists with "hands-on" experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with 'regular feature sections on: Biobusiness, Science and Innovation, Biodiscovery, Biodevelopment, Biomanufacturing plus special focuses on geographic or therapeutic territories. Established in 1997, EBR is now well-recognised for providing beneficial information to players in the bio-industry including entrepreneurial biopharmaceutical and more general life science companies, large pharma companies, supplier groups, regulators, investors, analysts and consultants, thus providing a unique forum for general review of the European life science sector on a regular basisEBR - April 2019
0308635056.png
»Ø¸´´ËÂ¥

» ±¾Ìû¸½¼þ×ÊÔ´Áбí

  • »¶Ó­¼à¶½ºÍ·´À¡£ºÐ¡Ä¾³æ½öÌṩ½»Á÷ƽ̨£¬²»¶Ô¸ÃÄÚÈݸºÔð¡£
    ±¾ÄÚÈÝÓÉÓû§×ÔÖ÷·¢²¼£¬Èç¹ûÆäÄÚÈÝÉæ¼°µ½ÖªÊ¶²úȨÎÊÌ⣬ÆäÔðÈÎÔÚÓÚÓû§±¾ÈË£¬Èç¶Ô°æÈ¨ÓÐÒìÒ飬ÇëÁªÏµÓÊÏ䣺xiaomuchong@tal.com
  • ¸½¼þ 1 : EBR_-_April_2019.pdf
  • 2019-03-21 15:53:31, 6.19 M

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
¼òµ¥»Ø¸´
alfzhang2Â¥
2019-03-22 12:32   »Ø¸´  
ÎåÐÇºÃÆÀ  ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
kklkimo3Â¥
2019-03-24 08:38   »Ø¸´  
ÎåÐÇºÃÆÀ  ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ uouonono µÄÖ÷Ìâ¸üÐÂ
¡î ÎÞÐǼ¶ ¡ï Ò»ÐǼ¶ ¡ï¡ï¡ï ÈýÐǼ¶ ¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 086000µ÷¼Á +3 7901117076 2026-03-26 3/150 2026-03-27 21:34 by Jianing_Mi
[¿¼ÑÐ] ʳƷ¹¤³Ìר˶һ־ԸÖк£Ñó309Çóµ÷¼Á +3 СÕÅzxyÕÅ 2026-03-26 5/250 2026-03-27 18:42 by СÕÅzxyÕÅ
[¿¼ÑÐ] 272Çóµ÷¼Á +7 ½Å»¬µÄÊØ·¨¹«Ãñ 2026-03-27 7/350 2026-03-27 17:23 by laoshidan
[¿¼ÑÐ] 308Çóµ÷¼Á +6 īīĮ 2026-03-27 6/300 2026-03-27 15:20 by caszguilin
[¿¼ÑÐ] 085600²ÄÁÏÓ뻯¹¤306 +10 z1z2z3879 2026-03-21 11/550 2026-03-27 11:31 by wangjy2002
[¿¼ÑÐ] 292Çóµ÷¼Á +4 ÇóÇóÁËÊÕÏÂÎÒ°É£ 2026-03-26 4/200 2026-03-27 10:37 by zhshch
[¿¼ÑÐ] Çóµ÷¼Á£¬Ò»Ö¾Ô¸ ÄϾ©º½¿Õº½Ìì´óѧ´óѧ £¬080500²ÄÁÏ¿ÆÑ§Ó빤³Ìѧ˶ +4 @taotao 2026-03-26 5/250 2026-03-27 08:10 by hypershenger
[¿¼ÑÐ] 351Çóµ÷¼Á +4 Âó¿Ë°¢ÀÚ 2026-03-24 4/200 2026-03-27 00:32 by wxiongid
[¿¼ÑÐ] µ÷¼ÁÇóÊÕÁô +7 ¹ûÈ»ÓÐÎÒ 2026-03-26 7/350 2026-03-27 00:26 by wxiongid
[¿¼ÑÐ] 081200-11408-276ѧ˶Çóµ÷¼Á +3 ´Þwj 2026-03-26 3/150 2026-03-26 19:57 by nihaoar
[¿¼ÑÐ] 085601Çóµ÷¼Á×Ü·Ö293Ó¢Ò»Êý¶þ +4 ¸ÖÌú´óÅÚ 2026-03-24 4/200 2026-03-26 16:28 by dick_runner
[¿¼ÑÐ] ²ÄÁÏ¿ÆÑ§Ó빤³Ì 317Çóµ÷¼Á +4 JKSOIID 2026-03-26 4/200 2026-03-26 15:58 by ²»³Ôô~µÄ؈
[¿¼ÑÐ] µ÷¼Á310 +3 ÎÂÈáµÄÍí°² 2026-03-25 4/200 2026-03-25 23:16 by peike
[¿¼ÑÐ] 303Çóµ÷¼Á +6 À¶É½Ô 2026-03-25 6/300 2026-03-25 22:47 by 418490947
[¿¼ÑÐ] ¿¼Ñе÷¼Á +6 À´ºÃÔËÀ´À´À´ 2026-03-21 7/350 2026-03-25 22:43 by 418490947
[¿¼ÑÐ] Çóµ÷¼Á +3 QiMing7 2026-03-25 3/150 2026-03-25 21:13 by ¸øÄãÄã×¢ÒâÐÝÏ¢
[¿¼ÑÐ] 293Çóµ÷¼Á +7 ¼ÓÒ»Ò»¾Å 2026-03-24 7/350 2026-03-25 12:02 by userper
[¿¼ÑÐ] »¯Ñ§µ÷¼Á +6 yzysaa 2026-03-21 6/300 2026-03-25 09:27 by aa331100
[¿¼ÑÐ] 292Çóµ÷¼Á +4 ¶ì¶ì¶ì¶î¶î¶î¶î¶ 2026-03-24 4/200 2026-03-24 16:41 by peike
[¿¼ÑÐ] Ò»Ö¾Ô¸070300Õã´ó»¯Ñ§358·Ö£¬Çóµ÷¼Á£¡ +4 ËÖËÖÓã.. 2026-03-21 4/200 2026-03-23 08:12 by Iveryant
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û